Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in Eur Radiol Retrieve available abstracts of 45 articles: HTML format

Single Articles

April 2023
1. SCHIRO S, Milanese G, Maddalo M, Ziglioli F, et al
   MR-based simplified extraprostatic extension evaluation: comparison of performances of different predictive models.
   Eur Radiol. 2023;33:2975-2984.
   PubMed     Abstract available
   
   
   
2. THIMANSSON E, Bengtsson J, Baubeta E, Engman J, et al
   Deep learning algorithm performs similarly to radiologists in the assessment of prostate volume on MRI.
   Eur Radiol. 2023;33:2519-2528.
   PubMed     Abstract available
   
   
   
3. PARK MY, Park KJ, Kim MH, Kim JK, et al
   Focal nodular enhancement on DCE MRI of the prostatectomy bed: radiologic-pathologic correlations and prognostic value.
   Eur Radiol. 2023;33:2985-2994.
   PubMed     Abstract available
   
   
   March 2023
4. QIN C, Goldberg O, Kakar G, Wan S, et al
   MRI fat fraction imaging of nodal and bone metastases in prostate cancer.
   Eur Radiol. 2023 Mar 16. doi: 10.1007/s00330-023-09527.
   PubMed     Abstract available
   
   
   
5. BAUCKNEHT M, Miceli A, Signori A, Albano D, et al
   Combined forced diuresis and late acquisition on [(68)Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study.
   Eur Radiol. 2023 Mar 9. doi: 10.1007/s00330-023-09516.
   PubMed     Abstract available
   
   
   February 2023
6. SUSHENTSEV N, Rundo L, Abrego L, Li Z, et al
   Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance.
   Eur Radiol. 2023 Feb 7. doi: 10.1007/s00330-023-09438.
   PubMed     Abstract available
   
   
   January 2023
7. LABUS S, Altmann MM, Huisman H, Tong A, et al
   A concurrent, deep learning-based computer-aided detection system for prostate multiparametric MRI: a performance study involving experienced and less-experienced radiologists.
   Eur Radiol. 2023;33:64-76.
   PubMed     Abstract available
   
   
   
8. GIGANTI F, Cole AP, Fennessy FM, Clinton T, et al
   Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship.
   Eur Radiol. 2023;33:461-471.
   PubMed     Abstract available
   
   
   November 2022
9. DENIFFEL D, Perlis N, Ghai S, Girgis S, et al
   Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
   Eur Radiol. 2022;32:7544-7554.
   PubMed     Abstract available
   
   
   
10. CORNUD F, Lefevre A, Camparo P, Barat M, et al
    Post-MRI transrectal micro-ultrasonography of transition zone PI-RADS > 2 lesions for biopsy guidance.
    Eur Radiol. 2022;32:7504-7512.
    PubMed     Abstract available
    
    
    October 2022
11. LIAO Z, Liu G, Ming B, Ma C, et al
    Evaluating prostate cancer bone metastasis using accelerated whole-body isotropic 3D T1-weighted Dixon MRI with compressed SENSE: a feasibility study.
    Eur Radiol. 2022 Oct 21. pii: 10.1007/s00330-022-09181.
    PubMed     Abstract available
    
    
    September 2022
12. GANDAGLIA G, Giannarini G, Stabile A, Montorsi F, et al
    Should we combine systematic with MRI-targeted biopsy? Implications for the management of patients with prostate cancer.
    Eur Radiol. 2022 Sep 15. pii: 10.1007/s00330-022-09096.
    PubMed    
    
    
    
13. PANEBIANCO V, Turkbey B
    Magnetic resonance imaging for prostate cancer recurrence: it's time for precision diagnostic with Prostate Imaging for Recurrence Reporting (PI-RR) score.
    Eur Radiol. 2022 Sep 1. pii: 10.1007/s00330-022-09095.
    PubMed    
    
    
    August 2022
14. ROEST C, Kwee TC, Saha A, Futterer JJ, et al
    AI-assisted biparametric MRI surveillance of prostate cancer: feasibility study.
    Eur Radiol. 2022 Aug 12. pii: 10.1007/s00330-022-09032.
    PubMed     Abstract available
    
    
    
15. RUD E, Noor D, Galtung KF, Ottosson F, et al
    Validating the screening criteria for bone metastases in treatment-naive unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases.
    Eur Radiol. 2022 Aug 8. pii: 10.1007/s00330-022-08945.
    PubMed     Abstract available
    
    
    July 2022
16. DONNERS R, Fotiadis N, Figueiredo I, Blackledge M, et al
    Optimising CT-guided biopsies of sclerotic bone lesions in cancer patients.
    Eur Radiol. 2022 Jul 26. pii: 10.1007/s00330-022-09011.
    PubMed     Abstract available
    
    
    
17. BEHESHTI M, Taimen P, Kemppainen J, Jambor I, et al
    Value of (68)Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [(18)F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study.
    Eur Radiol. 2022 Jul 21. pii: 10.1007/s00330-022-08982.
    PubMed     Abstract available
    
    
    
18. HAMZAOUI D, Montagne S, Granger B, Allera A, et al
    Prostate volume prediction on MRI: tools, accuracy and variability.
    Eur Radiol. 2022;32:4931-4941.
    PubMed     Abstract available
    
    
    June 2022
19. SUSHENTSEV N, McLean MA, Warren AY, Brodie C, et al
    The potential of hyperpolarised (13)C-MRI to target glycolytic tumour core in prostate cancer.
    Eur Radiol. 2022 Jun 22. pii: 10.1007/s00330-022-08929.
    PubMed     Abstract available
    
    
    May 2022
20. TO MNN, Kwak JT
    Biparametric MR signal characteristics can predict histopathological measures of prostate cancer.
    Eur Radiol. 2022 May 4. pii: 10.1007/s00330-022-08808.
    PubMed     Abstract available
    
    
    April 2022
21. MA W, Mao J, Yang J, Wang T, et al
    Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis.
    Eur Radiol. 2022 Apr 29. pii: 10.1007/s00330-022-08802.
    PubMed     Abstract available
    
    
    
22. BLEKER J, Kwee TC, Rouw D, Roest C, et al
    A deep learning masked segmentation alternative to manual segmentation in biparametric MRI prostate cancer radiomics.
    Eur Radiol. 2022 Apr 14. pii: 10.1007/s00330-022-08712.
    PubMed     Abstract available
    
    
    
23. PADHANI AR, Haider MA, Rouviere O
    Balancing the benefits and harms of MRI-directed biopsy pathways.
    Eur Radiol. 2022;32:2326-2329.
    PubMed     Abstract available
    
    
    
24. MICHALLEK F, Huisman H, Hamm B, Elezkurtaj S, et al
    Accuracy of fractal analysis and PI-RADS assessment of prostate magnetic resonance imaging for prediction of cancer grade groups: a clinical validation study.
    Eur Radiol. 2022;32:2372-2383.
    PubMed     Abstract available
    
    
    March 2022
25. GATTI M, Faletti R, Gentile F, Soncin E, et al
    mEPE-score: a comprehensive grading system for predicting pathologic extraprostatic extension of prostate cancer at multiparametric magnetic resonance imaging.
    Eur Radiol. 2022 Mar 15. pii: 10.1007/s00330-022-08595.
    PubMed     Abstract available
    
    
    
26. ZHENG H, Miao Q, Liu Y, Mirak SA, et al
    Multiparametric MRI-based radiomics model to predict pelvic lymph node invasion for patients with prostate cancer.
    Eur Radiol. 2022 Mar 3. pii: 10.1007/s00330-022-08625.
    PubMed     Abstract available
    
    
    February 2022
27. PENZKOFER T, Padhani AR, Turkbey B, Ahmed HU, et al
    Assessing the clinical performance of artificial intelligence software for prostate cancer detection on MRI.
    Eur Radiol. 2022 Feb 23. pii: 10.1007/s00330-022-08609.
    PubMed    
    
    
    
28. DE ROOIJ M, Barentsz JO
    PI-QUAL v.1: the first step towards good-quality prostate MRI.
    Eur Radiol. 2022;32:876-878.
    PubMed     Abstract available
    
    
    
29. GIGANTI F, Dinneen E, Kasivisvanathan V, Haider A, et al
    Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial.
    Eur Radiol. 2022;32:879-889.
    PubMed     Abstract available
    
    
    January 2022
30. BITTENCOURT LK, Guricova K, Zucker I, Durieux JC, et al
    Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naive men: a large cohort validation study.
    Eur Radiol. 2022 Jan 14. pii: 10.1007/s00330-021-08407.
    PubMed     Abstract available
    
    
    December 2021
31. MICHALLEK F, Huisman H, Hamm B, Elezkurtaj S, et al
    Prediction of prostate cancer grade using fractal analysis of perfusion MRI: retrospective proof-of-principle study.
    Eur Radiol. 2021 Dec 16. pii: 10.1007/s00330-021-08394.
    PubMed     Abstract available
    
    
    November 2021
32. HOSSEINZADEH M, Saha A, Brand P, Slootweg I, et al
    Deep learning-assisted prostate cancer detection on bi-parametric MRI: minimum training data size requirements and effect of prior knowledge.
    Eur Radiol. 2021 Nov 16. pii: 10.1007/s00330-021-08320.
    PubMed     Abstract available
    
    
    
33. BOSCHHEIDGEN M, Schimmoller L, Arsov C, Ziayee F, et al
    MRI grading for the prediction of prostate cancer aggressiveness.
    Eur Radiol. 2021 Nov 8. pii: 10.1007/s00330-021-08332.
    PubMed     Abstract available
    
    
    October 2021
34. CUOCOLO R, Stanzione A, Faletti R, Gatti M, et al
    MRI index lesion radiomics and machine learning for detection of extraprostatic extension of disease: a multicenter study.
    Eur Radiol. 2021;31:7575-7583.
    PubMed     Abstract available
    
    
    September 2021
35. HINZPETER R, Baumann L, Guggenberger R, Huellner M, et al
    Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study.
    Eur Radiol. 2021 Sep 24. pii: 10.1007/s00330-021-08245.
    PubMed     Abstract available
    
    
    
36. REISCHAUER C, Cancelli T, Malekzadeh S, Froehlich JM, et al
    How to improve image quality of DWI of the prostate-enema or catheter preparation?
    Eur Radiol. 2021;31:6708-6716.
    PubMed     Abstract available
    
    
    August 2021
37. JENTJENS S, Mai C, Ahmadi Bidakhvidi N, De Coster L, et al
    Prospective comparison of simultaneous [(68)Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer.
    Eur Radiol. 2021 Aug 10. pii: 10.1007/s00330-021-08140.
    PubMed     Abstract available
    
    
    July 2021
38. SUSHENTSEV N, Rundo L, Blyuss O, Nazarenko T, et al
    Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance.
    Eur Radiol. 2021 Jul 13. pii: 10.1007/s00330-021-08151.
    PubMed     Abstract available
    
    
    
39. BURA V, Caglic I, Snoj Z, Sushentsev N, et al
    MRI features of the normal prostatic peripheral zone: the relationship between age and signal heterogeneity on T2WI, DWI, and DCE sequences.
    Eur Radiol. 2021;31:4908-4917.
    PubMed     Abstract available
    
    
    May 2021
40. PENZKOFER T, Padhani AR, Turkbey B, Haider MA, et al
    ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging.
    Eur Radiol. 2021 May 15. pii: 10.1007/s00330-021-08021.
    PubMed     Abstract available
    
    
    April 2021
41. WALLSTROM J, Geterud K, Kohestani K, Maier SE, et al
    Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Goteborg prostate cancer screening 2 trial.
    Eur Radiol. 2021 Apr 23. pii: 10.1007/s00330-021-07907.
    PubMed     Abstract available
    
    
    
42. ALBERTS I, Hunermund JN, Sachpekidis C, Mingels C, et al
    The influence of digital PET/CT on diagnostic certainty and interrater reliability in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer.
    Eur Radiol. 2021 Apr 15. pii: 10.1007/s00330-021-07870.
    PubMed     Abstract available
    
    
    January 2021
43. STEINBERG RL, Rasmussen RG, Johnson BA, Ghandour R, et al
    Prospective performance of clear cell likelihood scores (ccLS) in renal masses evaluated with multiparametric magnetic resonance imaging.
    Eur Radiol. 2021;31:314-324.
    PubMed     Abstract available
    
    
    
44. SCHELB P, Wang X, Radtke JP, Wiesenfarth M, et al
    Simulated clinical deployment of fully automatic deep learning for clinical prostate MRI assessment.
    Eur Radiol. 2021;31:302-313.
    PubMed     Abstract available
    
    
    November 2020
45. DELLI PIZZI A, Mastrodicasa D, Marchioni M, Primiceri G, et al
    Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach.
    Eur Radiol. 2020 Nov 19. pii: 10.1007/s00330-020-07473.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: